Asen Bagashev
Vice President, In Vivo Cell Therapies Velvet Therapeutics
Dr. Bagashev is the VP of In Vivo Cell Therapies at Velvet Therapeutics, where he leads strategic development of next-generation CAR based immunotherapies. He brings extensive expertise in immuno-oncology and cell therapies, with publications spanning engineered CAR constructs and immune-modulating platforms. Previously, at Carisma Therapeutics, he advanced preclinical proof-of-concept in vivo CAR-M programs for solid tumors using mRNA/LNP delivery systems. Before Carisma Therapeutics, he contributed to translational ex vivo CAR-T research at Children’s Hospital of Philadelphia and the University of Pennsylvania. His work integrates synthetic biology, vector engineering, and tumor immunology to develop scalable and affordable In Vivo CAR cellular therapies for solid tumors.
Seminars
- Comparing DNA‑based nanoparticle delivery with LNP and lentiviral systems, enabling stronger, longer yet non‑integrating gene expression to enhance therapeutic optionality
- Revealing emerging biodistribution insights including an unexpected liver‑escape profile, expanding understanding of tissue targeting and informing future mechanism‑of‑action work
- Highlighting manufacturing simplicity, safety signals, and unpublished preclinical data, equipping attendees with actionable perspectives on platform readiness and translational potential
